ClinicalTrials.gg
Active, not recruitingNCT05232838Updated Jun 19, 2025

US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

An interventional study of eShunt Implant in Hydrocephalus, Normal Pressure and Hydrocephalus, sponsored by CereVasc Inc. Active, not recruiting at 11 sites in United States. Open to participants aged 65 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by CereVasc Inc · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
65 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Hydrocephalus, Normal Pressure with a site in United States — 4 open to participants now, 6 under way, none of them phase 3. Hydrocephalus, Normal Pressure · United States.

Planned enrollment
5th of 15
50 · median 30
Started
2022
with 1 other
No phase
10 of 24
2 open now
Registered
21st of 24
by date
Lead sponsor
2 of 24
CereVasc Inc

Among the 24 studies in Hydrocephalus, Normal Pressure with a site in United States, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is one of 10 with no phase, and was the 21st registered.

Hydrocephalus, Normal Pressure

78 studies on the registry are indexed under Hydrocephalus, Normal Pressure; 20 are open to participants now.

Browse Hydrocephalus, Normal Pressure studies →

Open to participants now

4 of the 24 studies in Hydrocephalus, Normal Pressure with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Hydrocephalus, Normal Pressure studies recruiting now, 12 (75%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 65 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hydrocephalus, Normal Pressure with a site in United States, or all of them as a file.
02

Study summary

The eShunt® System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.

Read the detailed description

This is a prospective, non-randomized, open-label, multi-center, pilot study in subjects with normal pressure hydrocephalus for whom a traditional cerebrospinal fluid (CSF) shunt implant is indicated.

Up to 50 subjects will receive the eShunt Implant at up to 12 investigational sites. It is anticipated that up to 250 patients may need to be enrolled (consented) in order to result in 50 subjects who qualify according to the inclusion/exclusion criteria. Subjects will return for five follow-up visits in the first year and then continue to attend visits every six months until the study is closed or up to five years post-implantation.

The study objectives are to demonstrate safety of the eShunt Procedure, as well as demonstrate safety and efficacy of the eShunt Implant in a small sample of patients. Subjects will be followed long-term; primary analysis results will be used to support additional studies.

03

Conditions studied

  • Hydrocephalus, Normal Pressure
  • Hydrocephalus

Keywords

  • eShunt
  • Minimally invasive shunt
  • Endovascular shunt
04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients 65-85 years old for whom traditional CSF shunt placement is indicated based upon a diagnostic normal pressure hydrocephalus (NPH) evaluation
  2. Patient or legally authorized representative is able and willing to provide written
  3. History or evidence of gait impairment duration ≥6 months
  4. Clinical presentation consistent with NPH including 2 or more of the clinical triad (i.e., history of gait disturbance, progressive mental deterioration, and urinary urgency or incontinence), together with:

    1. Brain MRI signs of ventricular enlargement disproportionate to cerebral atrophy (Evans' Index >0.3) and the absence of severe hippocampal atrophy
    2. Pre-procedure spinal tap test or lumbar drain with subsequent gait disturbance improvement (Timed Up and Go Test) of at least 20%
    3. CSF opening pressure ≥8 cmH2O
    4. Baseline cognitive evaluation assessed by (MoCA) test score ≥12
  5. Pre-procedure MRI confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by subject screening committee (SSC)
  6. Pre-procedure CT confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by SSC

Exclusion criteria

Exclusion Criteria:

  1. Unable to walk 10 meters (33 feet) with or without an assistive device
  2. Signs or symptoms of obstructive hydrocephalus
  3. Active systemic infection or infection detected in CSF
  4. Prior or existing shunts, endoscopic third ventriculostomy, or any previous surgical intervention for hydrocephalus
  5. or to heparin or radiographic contrast agents which cannot be adequately pre-medicated, desensitized or where no alternative is available
  6. Occlusion or stenosis of the internal jugular vein
  7. Venous distension in the neck on physical exam
  8. Atrial septal defect or patent foramen ovale identified on cardiac echocardiogram
  9. History of bleeding diatheses, coagulopathy or will refuse blood transfusion in cases of emergency
  10. Stroke or within 180 days of eShunt Procedure
  11. Presence of a deep vein thrombosis superior to the popliteal vein
  12. (INR) or Partial Thromboplastin Time (PTT) results outside of normal range (INR 0.8-1.4; PTT 25-35 seconds)
  13. Presence of a posterior fossa tumor or mass
  14. \< 1 year
  15. Currently participating in another drug or device trial that could conflict with study data collection or follow-up
  16. Other medical illnesses that may cause the patient to be non-compliant with the protocol or confound data interpretation
  17. Unwilling or unable to comply with follow-up requirements
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    The Treatment Arm receives the eShunt Implant.

    Device: eShunt Implant

Interventions

  • DeviceeShunt Implant

    The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.

06

What researchers measure

Primary outcomes

  1. Device and/or procedure-related serious adverse events (SAEs)

    Rate of occurrence of device and/or procedure-related serious adverse events (SAEs)

    Time frame: 90 days following eShunt Implant deployment

Secondary outcomes

  1. Number of participants with abnormal MRI findings

    Number of participants with abnormal MRI findings and descriptive summaries of findings

    Time frame: 90 days following eShunt Implant deployment

  2. Number of participants with abnormal CT findings

    Number of participants with abnormal CT findings and descriptive summaries of findings

    Time frame: 90 days following eShunt Implant deployment

  3. Number of participants with clinically significant abnormal complete blood count (CBC) results

    Number of participants with clinically significant abnormal results and descriptive summaries of CBC results

    Time frame: 90, 180, and 365 days following eShunt Implant deployment

  4. Number of participants with clinically significant abnormal blood chemistry results

    Number of participants with clinically significant abnormal findings and descriptive summaries of blood chemistry results

    Time frame: 90, 180, and 365 days following eShunt Implant deployment

  5. Number of participants with clinically significant abnormal neurological exam findings

    Number of participants with clinically significant abnormal findings and descriptive summaries of neurological exam findings

    Time frame: 90, 180, and 365 days following eShunt Implant deployment and at study completion

  6. Number of participants with adverse events

    Tabulation of all adverse events

    Time frame: 90, 180 and 365 days following eShunt Implant deployment and at study completion

  7. Change in gait compared to baseline

    Change in gait compared to baseline as measured by the duration in seconds of the Timed Up and Go Test (shorter durations indicate improvement (increased mobility))

    Time frame: 90, 180 and 365 days following eShunt Implant deployment

  8. Change in cognitive ability compared to baseline

    Change in cognitive ability compared to baseline as measured by Montreal Cognitive Assessment (MoCA) scores (scores range from 0-30; higher scores indicate improvement (less cognitive disability))

    Time frame: 90, 180 and 365 days following eShunt Implant deployment

  9. Change in urinary symptoms compared to baseline

    Change in urinary symptoms compared to baseline as measured by the Neurogenic Bladder Symptom Score (NBSS) (scores range from 0-28; lower scores indicate improvement (fewer symptoms))

    Time frame: 90, 180 and 365 days following eShunt Implant deployment

  10. Change in Modified Rankin Scale compared to baseline

    Change in degree of disability compared to baseline as measured by Modified Rankin Scale (mRS) scores (scores range from 0-6; lower scores indicate improvement (less disability))

    Time frame: 90, 180 and 365 days following eShunt Implant deployment

07

Study locations

11 sites
08

References and documents

Publications

  • Heilman CB, Basil GW, Beneduce BM, Malek AM. Anatomical characterization of the inferior petrosal sinus and adjacent cerebellopontine angle cistern for development of an endovascular transdural cerebrospinal fluid shunt. J Neurointerv Surg. 2019 Jun;11(6):598-602. doi: 10.1136/neurintsurg-2018-014445. Epub 2019 Jan 9. PubMed 30626626 ↗
  • Lylyk P, Lylyk I, Bleise C, Scrivano E, Lylyk PN, Beneduce B, Heilman CB, Malek AM. First-in-human endovascular treatment of hydrocephalus with a miniature biomimetic transdural shunt. J Neurointerv Surg. 2022 May;14(5):495-9. doi: 10.1136/neurintsurg-2021-018136. Epub 2021 Dec 3. PubMed 34862267 ↗
  • Welk B, Morrow S, Madarasz W, Baverstock R, Macnab J, Sequeira K. The validity and reliability of the neurogenic bladder symptom score. J Urol. 2014 Aug;192(2):452-7. doi: 10.1016/j.juro.2014.01.027. Epub 2014 Feb 8. PubMed 24518764 ↗
  • Welk B, Lenherr S, Elliott S, Stoffel J, Gomes CM, de Bessa J, Cintra LKL, Myers JB; Neurogenic Bladder Research Group. The creation and validation of a short form of the Neurogenic Bladder Symptom Score. Neurourol Urodyn. 2020 Apr;39(4):1162-1169. doi: 10.1002/nau.24336. Epub 2020 Mar 20. PubMed 32196732 ↗
  • Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. PubMed 15817019 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jun 2025, 37 months.

Of 21 interventional studies with no phase under Hydrocephalus, Normal Pressure, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2022
First posted
Feb 10, 2022
StartActual
Apr 20, 2022
Primary completionActual
Jun 15, 2025
CompletionEst.
Jun 30, 2030
Last update
Jun 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05232838
Lead sponsor
CereVasc Inc
Collaborators
AlvaMed, Inc., Simplified Clinical Data Systems, LLC
Responsible party
Sponsor
First posted
Feb 10, 2022
Start date
Apr 20, 2022
Primary completion
Jun 15, 2025
Completion
Jun 30, 2030 (estimated)
Last update
Jun 19, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion